公开(公告)号：US20230011700A1

公开(公告)日：2023-01-12

申请号：US17933033

申请日：2022-09-16

Applicant: NantBio, Inc. ,  Nant Holdings IP, LLC

Inventor： Kayvan Niazi ,  Shahrooz Rabizadeh ,  Nicholas J. Witchey

IPC: G01N33/574 ,  G01B9/02 ,  G01B11/06 ,  G01N33/50

Abstract: Systems and methods for predicting an immune response against a tumor in a patient having the tumor are provided. The relative mass or changes of mass of tumor cells or immune cell in the tumor can be ex vivo observed, and an immune status of the tumor can be determined based on the mass of tumor cells or immune cell. The immune status can provide a guidance to predict the immune response against the tumor in the patient.

公开(公告)号：US12053512B2

公开(公告)日：2024-08-06

申请号：US16465675

申请日：2017-12-05

Applicant: NantBio, Inc. ,  Nant Holdings IP, LLC ,  NantOmics, LLC

Inventor： Kayvan Niazi ,  Nicholas J. Witchey ,  Stephen Charles Benz ,  Shahrooz Rabizadeh

IPC: G01N33/50 ,  A61K39/00 ,  G01N33/569

CPC classification number: A61K39/0011 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/56977 ,  A61K2039/5158 ,  A61K2039/605 ,  A61K2039/6081

Abstract: The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by: a) obtaining neoepitope sequence data from the tumor of a subject; b) obtaining immune competent cells; c) using the neoepitope sequence data to generate a neoepitope presentation system; d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and e) quantifying the triggering of the immune response from the contacted immune competent cells.

公开(公告)号：US20200011868A1

公开(公告)日：2020-01-09

申请号：US16470072

申请日：2017-12-17

Applicant: NANT HOLDINGS IP, LLC ,  NANTBIO, INC.

Inventor： Kayvan NIAZI ,  Shahrooz RABIZADEH ,  Nicholas J. Witchey

IPC: G01N33/574 ,  G01N33/50 ,  G01B9/02 ,  G01B11/06

Abstract: Systems and methods for predicting an immune response against a tumor in a patient having the tumor are provided. The relative mass or changes of mass of tumor cells or immune cell in the tumor can be ex vivo observed, and an immune status of the tumor can be determined based on the mass of tumor cells or immune cell. The immune status can provide a guidance to predict the immune response against the tumor in the patient.

公开(公告)号：US20240350603A1

公开(公告)日：2024-10-24

申请号：US18761799

申请日：2024-07-02

Applicant: NantBio, Inc. ,  Nant Holdings IP, LLC ,  Nantomics LLC

Inventor： Kayvan Niazi ,  Nicholas J. Witchey ,  Stephen Charles Benz ,  Shahrooz Rabizadeh

IPC: A61K39/00 ,  G01N33/50 ,  G01N33/569

CPC classification number: A61K39/0011 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/56977 ,  A61K2039/5158 ,  A61K2039/605 ,  A61K2039/6081

Abstract: The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by:



a) obtaining neoepitope sequence data from the tumor of a subject;
b) obtaining immune competent cells;
c) using the neoepitope sequence data to generate a neoepitope presentation system;
d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and
e) quantifying the triggering of the immune response from the contacted immune competent cells.

公开(公告)号：US12044687B1

公开(公告)日：2024-07-23

申请号：US16818441

申请日：2020-03-13

Applicant: NantBio, Inc.

Inventor： Clifford Anders Olson ,  Kayyan Niazi ,  Nicholas J. Witchey ,  Wael Tadros

IPC: G01N33/68 ,  C12N5/10 ,  C12N15/10 ,  C12Q1/6897 ,  G01N21/64 ,  G01N33/50

CPC classification number: G01N33/6872 ,  C12N5/10 ,  C12N15/1006 ,  C12Q1/6897 ,  G01N21/64 ,  G01N33/5091 ,  G01N2333/705

Abstract: The present disclosure relates to recombinant production reporter cells comprising a logic gate such that an expressible sequence (e.g., a reporter gene) is expressed after the occurrence of triggering event related to a stage of production or an environmental condition of a biological production system. Nucleic acids, kits, and methods for making and using the recombinant production reporter cells are also disclosed herein.

公开(公告)号：US11480572B2

公开(公告)日：2022-10-25

申请号：US16470072

申请日：2017-12-17

Applicant: NANT HOLDINGS IP, LLC ,  NANTBIO, INC.

Inventor： Kayvan Niazi ,  Shahrooz Rabizadeh ,  Nicholas J. Witchey

IPC: G01N33/574 ,  G01B9/02 ,  G01B11/06 ,  G01N33/50

Abstract: Systems and methods for predicting an immune response against a tumor in a patient having the tumor are provided. The relative mass or changes of mass of tumor cells or immune cell in the tumor can be ex vivo observed, and an immune status of the tumor can be determined based on the mass of tumor cells or immune cell. The immune status can provide a guidance to predict the immune response against the tumor in the patient.